8-K: Waystar Exceeds Q3 Expectations, Raises Full-Year Guidance

Waystar Holding Corp. reported strong third-quarter 2025 results, surpassing revenue and margin guidance and raising its full-year financial outlook.

Summary

• Waystar Holding Corp. announced third-quarter 2025 revenue of $268.7 million, marking a 12% year-over-year increase.
• Net income for Q3 2025 reached $30.6 million, with a GAAP net income per diluted share of $0.17 and a net income margin of 11%.
• Non-GAAP net income was $67.8 million, translating to $0.37 per diluted share.
• Adjusted EBITDA stood at $112.7 million, achieving an adjusted EBITDA margin of 42%.
• Cash flow from operations was $82 million, and unlevered free cash flow was $96 million.
• The company reported 1,306 clients contributing over $100,000 in LTM revenue, an 11% increase year-over-year.
• Net revenue retention rate (NRR) was 113%.
• Subscription revenue grew 14% year-over-year to $134.5 million, while volume-based revenue increased 10% to $132.3 million.
• Waystar raised its full fiscal year 2025 guidance, expecting total revenue between $1.085 billion and $1.093 billion.
• Adjusted EBITDA for the full year is now projected to be between $451 million and $455 million.
• Non-GAAP net income guidance for 2025 is set between $271 million and $274 million, with diluted non-GAAP net income per share between $1.46 and $1.47.

Sentiment

Score: 9

Explanation: The sentiment is highly positive due to strong financial performance exceeding guidance, significant year-over-year growth in key metrics, successful strategic integration, and a raised full-year outlook, all communicated with confident management commentary.

Positives

• Achieved double-digit revenue growth of 12% year-over-year, reaching $268.7 million in Q3 2025.
• Significantly improved GAAP net income to $30.6 million in Q3 2025 from $5.4 million in Q3 2024.
• Increased net income margin to 11% in Q3 2025 from 2.3% in Q3 2024.
• Maintained strong adjusted EBITDA margin of 42% in Q3 2025.
• Outpaced previous guidance on both revenue and margins for the third quarter.
• Successfully integrating Iodine Software, enhancing the AI-powered platform and unlocking new growth opportunities.
• Raised full-year 2025 guidance for total revenue, adjusted EBITDA, and non-GAAP net income, indicating strong confidence in future performance.
• Grew client count with over $100,000 in LTM revenue by 11% year-over-year to 1,306 clients.
• Maintained a healthy Net Revenue Retention Rate (NRR) of 113%, demonstrating strong client satisfaction and expansion.
• Subscription revenue, a key recurring revenue stream, grew by 14% year-over-year.

Risks

• Operating in a highly competitive industry.
• Ability to retain existing clients and attract new clients.
• Ability to successfully execute business strategies to grow.
• Risks related to accurately assessing and successfully integrating acquisitions, including Iodine Software.
• Ability to establish and maintain strategic relationships.
• Dependence on the growth and success of clients and overall healthcare transaction volumes.
• Impact of consolidation in the healthcare industry.
• Variable length of the selling cycle to secure new client agreements.
• Implementation cycle dependent on clients' timing and resources.
• Dependence on the senior management team and key employees, and ability to attract and retain highly skilled employees.
• Accuracy of estimates and assumptions used to determine the size of the total addressable market.
• Ability to develop and market new solutions or enhance existing ones to respond to technological changes or evolving industry standards.
• Interoperability, connectivity, and integration of solutions with clients' and vendors' networks and infrastructures.
• Performance and reliability of internet, mobile, and other infrastructure.
• Consequences if the company cannot obtain, process, use, disclose, or distribute highly regulated data.
• Reliance on certain third-party vendors and providers.
• Potential for errors or malfunctions in products and solutions.
• Failure by clients to obtain proper permissions or provide accurate and appropriate information.
• Potential for embezzlement, identity theft, or other illegal behavior by employees or vendors.
• Compliance with applicable rules of the National Automated Clearing House Association and card network requirements.
• Increases in card network fees and other changes to fee arrangements.
• Effect of payer and provider conduct which the company cannot control.
• Privacy concerns and security breaches or incidents relating to the platform.
• Complex and evolving laws and regulations regarding privacy, data protection, and cybersecurity.
• Ability to adequately protect and enforce intellectual property rights.
• Ability to use or license data and integrate third-party technologies.
• Use of open source software.
• Legal proceedings initiated by third parties alleging intellectual property infringement.
• Claims that employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties.
• Operating in a heavily regulated industry.
• Uncertain and evolving healthcare regulatory and political framework.
• Reduced revenues in response to changes to the healthcare regulatory landscape.
• Legal, regulatory, and other proceedings that could result in adverse outcomes.
• Consumer protection laws and regulations.
• Contractual obligations requiring compliance with certain provisions of the Bank Secrecy Act and anti-money laundering laws and regulations.
• Existing laws that regulate the ability to engage in certain marketing activities.
• Full compliance with website accessibility standards.
• Any changes in tax rates, adoption of new tax legislation, or exposure to additional tax liabilities.
• Limitations on the ability to use net operating losses to offset future taxable income.
• Losses due to asset impairment charges.
• Restrictive covenants in the agreements governing credit facilities.
• Interest rate fluctuations.
• Unavailability of additional capital on acceptable terms or at all.
• Impact of general macroeconomic conditions.
• Actions of certain significant investors, who may have different interests than other holders of securities.
• Status as an 'emerging growth company' and potential impact on investor attractiveness.

Future Outlook

Waystar has raised its full fiscal year 2025 guidance, now expecting total revenue between $1.085 billion and $1.093 billion, adjusted EBITDA between $451 million and $455 million, non-GAAP net income between $271 million and $274 million, and diluted non-GAAP net income per share between $1.46 and $1.47. This revised outlook reflects confidence in continued demand and focused execution, building on strong Q3 performance.

Management Comments

• "Waystar delivered another quarter of double-digit revenue growth and strong margins, outpacing our guidance on both measures."
• "Our integration of Iodine Software is well underway, enhancing Waystar's AI-powered platform and unlocking new opportunities to drive profitable growth."
• "Continuing demand and focused execution reinforce our confidence in raising our full-year guidance."

Industry Context

Waystar operates in the rapidly evolving healthcare payment software industry, which is increasingly leveraging AI to simplify complex payment processes. The company's strong double-digit revenue growth and high margins suggest it is effectively capitalizing on the demand for efficient healthcare payment solutions. The successful integration of Iodine Software indicates a strategic move to enhance its AI capabilities, positioning it well within a competitive landscape focused on technological innovation and operational efficiency for healthcare providers.

Comparison to Industry Standards

• The filing highlights Waystar's significant market presence, serving approximately 30,000 clients, representing over 1 million distinct providers, including 17 of 20 institutions on the U.S. News Best Hospitals list.
• Waystar's platform annually processes over 6 billion healthcare payment transactions, including over $1.8 trillion in annual gross claims and spanning approximately 50% of U.S. patients, indicating a substantial footprint in the U.S. healthcare market.
• Specific comparable companies, projects, or direct industry benchmarks for financial performance (e.g., revenue growth rates, EBITDA margins) are not provided within the filing to allow for a direct assessment against global industry standards.

Legal Proceedings

• The 'Forward-Looking Statements' section mentions general risks related to 'legal proceedings initiated by third parties alleging that we are infringing or otherwise violating their intellectual property rights' and 'legal, regulatory, and other proceedings that could result in adverse outcomes,' but no specific current legal proceedings are detailed in the filing.

Related Party Transactions

• The financial statements show 'Related party interest expense' of $902 thousand for the three months ended September 30, 2025, and $2,475 thousand for the nine months ended September 30, 2025.
• There is also 'Related party current portion of long-term debt' of $569 thousand and 'Related party long-term debt, net, less current portion' of $55,783 thousand as of September 30, 2025.

Stakeholder Impact

• **Shareholders:** Positive impact due to strong financial performance, increased profitability, and raised full-year guidance, which could lead to increased share value.
• **Employees:** The successful integration of Iodine Software and continued growth may indicate job stability and potential for growth opportunities within the company.
• **Customers (Healthcare Providers):** Continued enhancement of Waystar's AI-powered platform and solutions, particularly with the Iodine Software integration, suggests improved service offerings and efficiency in healthcare payments.
• **Creditors:** Improved financial health, including increased cash flow from operations and adjusted EBITDA, strengthens the company's ability to meet its debt obligations, as reflected in the improved adjusted net leverage ratio of 1.9x.

Next Steps

• Waystar's financial results will be discussed on a conference call scheduled for 4:30 p.m. Eastern Daylight Time on October 29, 2025.
• A live audio conference call webcast will be available on Waystar's website, with an archived version available for later listening.
• The company routinely posts important information, including corporate and investor presentations and financial information, on its Investor Relations website and intends to use it for disclosing material, non-public information.

Key Dates

Recommendation

Waystar's Q3 2025 results demonstrate exceptional performance, significantly exceeding prior guidance on both revenue and margins. The company's decision to raise its full-year 2025 guidance across key financial metrics (revenue, adjusted EBITDA, non-GAAP net income) signals strong underlying business momentum and management confidence. The successful integration of Iodine Software is enhancing its AI-powered platform, positioning Waystar for continued profitable growth in the critical healthcare payment software market. With double-digit revenue growth, robust margins, healthy client retention (NRR of 113%), and a clear positive outlook, the company exhibits strong fundamentals and strategic execution. The improved adjusted net leverage ratio also indicates a strengthening balance sheet. These factors collectively suggest a compelling investment opportunity.

Keywords

Healthcare Payment Software, Revenue Growth, Adjusted EBITDA, Net Income, Financial Guidance, Q3 Earnings, Iodine Software Integration, AI-powered Platform, Net Revenue Retention, Cash Flow, SEC Filing, WAY Nasdaq